- Conditions
- Cancer
- Interventions
- 5-FU, Atezolizumab, Bevacizumab, Carboplatin, Leucovorin, Nab-paclitaxel, Oxaliplatin, Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2089–2112
of 7,462
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumors, Relapsed/Refractory Sarcomas
- Interventions
- Vorinostat and Etoposide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Orlando, Florida + 7 more
- Conditions
- Hemophilia A
- Interventions
- Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 16 Years and older · Male only
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
- Conditions
- Breast Cancer
- Interventions
- Cisplatin, Rucaparib
- Drug
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 27
- States / cities
- Fullerton, California • Los Angeles, California • Santa Maria, California + 22 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- MEDI7510, IIV, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 1,900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 30
- States / cities
- Sacramento, California • San Francisco, California • Aurora, Colorado + 27 more
- Conditions
- Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
- Interventions
- Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
- Other · Drug
- Lead sponsor
- University Health Network, Toronto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 20 more
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Best Practice, Exercise Counseling, Exercise Intervention, Magnetic Resonance Imaging, Neuropathy Assessment, Questionnaire Administration
- Other · Procedure
- Lead sponsor
- University of Rochester NCORP Research Base
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 93
- States / cities
- Fresno, California • Martinez, California • Roseville, California + 70 more
- Conditions
- Covid19
- Interventions
- Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
- Conditions
- Parkinson's Disease (PD)
- Interventions
- adaptive DBS (aDBS)
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Type 2 Diabetes
- Interventions
- Placebo Attention Control, Supervised Exercise Training
- Behavioral · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- EPIC-HF Patient-facing Tool, PROMPT-HF Clinician-facing Alert
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Walnut Creek, California • Aurora, Colorado • New Haven, Connecticut + 2 more
- Conditions
- Influenza
- Interventions
- 13 valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 59 Years
- Enrollment
- 1,116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 41
- States / cities
- Chandler, Arizona • Rolling Hills Estates, California • Aurora, Colorado + 29 more
- Conditions
- Lupus Erythematosus, Systemic, Lupus Nephritis
- Interventions
- CC-97540, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 28 more
- Conditions
- Colorectal Cancer
- Interventions
- cetuximab, Irinotecan
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 116
- States / cities
- Tucson, Arizona • Pine Bluff, Arkansas • Bakersfield, California + 104 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Flovent, Placebo
- Drug · Other
- Lead sponsor
- Marc Rothenberg, MD
- Other
- Eligibility
- 3 Years to 30 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors
- Interventions
- ziftomenib, imatinib mesylate
- Drug
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Momelotinib, Placebo to match danazol, Danazol, Placebo to match momelotinib
- Drug
- Lead sponsor
- Sierra Oncology LLC - a GSK company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Irvine, California • Los Angeles, California + 14 more
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
- Interventions
- Autogene cevumeran, Atezolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Tumors With CDK4/6 Pathway Activation
- Interventions
- LEE011
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
- Conditions
- Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
- Interventions
- Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, External Beam Radiation Therapy, Ganitumab, Ifosfamide, Stereotactic Radiosurgery, Therapeutic Surgical Procedure, Vincristine, Vincristine Sulfate
- Drug · Radiation · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 50 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 298
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 203 more
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- Treosulfan
- Drug
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more
- Conditions
- Inpatient Pediatric Care, Isolation, Feasibility Studies
- Interventions
- Reality PAWS Program via Meta Quest 3 VR
- Device
- Lead sponsor
- Children's Hospital Colorado
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Aurora, Colorado
- Conditions
- Post Procedural Erythema
- Interventions
- Not listed
- Lead sponsor
- Acorn Biolabs Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 24 more
- Conditions
- Osteoarthritis
- Interventions
- tanezumab, Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 97
- States / cities
- Jonesboro, Arkansas • Aurora, Colorado • Centennial, Colorado + 42 more